齐拉西酮和奥氮平治疗早期精神分裂症及对阴性症状量表评分影响分析
Ziprasidone and olanzapine in the treatment of early schizophrenia and their effects on the score of negative symptom scale
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2021, 48(6) |
| 作者 |
|
| 作者单位 |
河南省洛阳市第五人民医院 精神三科 ;
|
| 摘要 |
【摘要】目的：探讨早期精神分裂症患者采用齐拉西酮和奥氮平治疗的价值。方法：纳入120例早期精神分裂症患者研究（2019年8月~2021年6月），按双盲法分为2组，以奥氮平治疗者60例纳入对照组，采用齐拉西酮+奥氮平治疗者60例纳入观察组，统计两组临床疗效、副反应量表（Treatment Emergent Symptom Scale，TESS）评分、阴性症状量表评分（Scale for Assessment of Negative Symptoms，SANS）、临床指标。结果：（1）临床疗效：观察组（98.33%）高于对照组（85.00%），组间对比P<0.05。（2）SANS评分：观察组（48.25±10.34）分低于对照组（55.19±10.82）分，组间对比P<0.05。（3）TESS评分：观察组治疗后4周（7.27±2.88）分、治疗后8周（2.21±0.11）分低于对照组（9.61±3.62）、（2.85±0.32）分，组间对比P<0.05。（4）临床指标：观察组甘油三酯（Triglyceride，TG）、总胆固醇（Total cholesterol，TC）、低密度脂蛋白胆固醇（Low Density Lipoprotein Cholesterol，LDL-C）、血糖（Factry Business Customer，FBC）、肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、白介素-2（Interleukin-2，IL-2）、白介素-6（Interleukin-6，IL-6）低于对照组，组间对比P<0.05。结论：齐拉西酮和奥氮平联合在早期精神分裂症治疗中可行性较高，可改善其阴性症状评分及副反应评分，亦可降低血糖及血脂水平，值得借鉴及参考。
|
| Abstract |
[Abstract] Objective: To explore the value of ziprasidone and olanzapine in the treatment of early schizophrenia. Methods: 120 patients with early schizophrenia were included in the study (August 2019 ~ June 2021). They were divided into two groups according to the double-blind method. 60 patients treated with olanzapine were included in the control group and 60 patients treated with ziprasidone + olanzapine were included in the observation group. The clinical efficacy, treatment emergent symptom scale (TESS) scores and Scale for assessment of negative symptoms (SANS), clinical indicators. Results: (1) clinical efficacy: the observation group (98.33%) was higher than the control group (85.00%), and the comparison between groups was p < 0.05. (2) Sans score: the score of the observation group (48.25 ± 10.34) was lower than that of the control group (55.19 ± 10.82), P < 0.05. (3) Tess score: the scores of the observation group at 4 weeks (7.27 ± 2.88) and 8 weeks (2.21 ± 0.11) after treatment were lower than those of the control group (9.61 ± 3.62) and (2.85 ± 0.32) (P<0.05). (4) Clinical indicators: triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), blood glucose (FBC) and tumor necrosis factor (TNF) in the observation group- α（tumor necrosis factor- α， TNF- α）、 The levels of interleukin-2 (IL-2) and interleukin-6 (IL-6) in the control group were lower than those in the control group (P<0.05). Conclusion: the combination of ziprasidone and olanzapine is feasible in the treatment of early schizophrenia. It can improve its negative symptom score and side effect score, and reduce the level of blood glucose and blood lipid, which is worthy of reference.
|
| 关键词 |
关键词：齐拉西酮；奥氮平；早期精神分裂症；阴性症状量表评分；副反应
|
| KeyWord |
Keywords: ziprasidone; Olanzapine; Early schizophrenia; Negative symptom scale score; side reaction
|
| 基金项目 |
|
| 页码 |
1025-1027 |
翟瑛*.
齐拉西酮和奥氮平治疗早期精神分裂症及对阴性症状量表评分影响分析 [J].
国际精神病学杂志.
2021; 48; (6).
1025 - 1027.